Current Research Studies

BrainChild-04: A Phase 1 Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors

BrainChild-04

  • Condition(s): Atypical Teratoid/Rhabdoid Tumor, Brain Tumor, CNS Embryonal Tumors, CNS Germ Cell Tumors, Choroid Plexus Tumors, Diffuse Intrinsic Pontine Glioma (DIPG), Diffuse Midline Glioma (DMG), Ependymoma, High-Grade Glioma, Medulloblastoma, Newly diagnosed, Recurrent and/or Refractory
  • Phase: I
  • Clinicaltrials.gov ID: NCT05768880

What is the goal of the study?

Seattle Children's is testing a CAR T-cell therapy, called SC-CAR4BRAIN, in children and young adults with recurrent or refractory central nervous system (CNS) tumors, including diffuse intrinsic pontine glioma (DIPG) and diffuse midline glioma (DMG). Through this phase 1 trial, researchers are working to answer these questions: Is SC-CAR4BRAIN safe to give to children and young adults with DIPG, DMG or relapsed or refractory CNS tumors? What is the best dose of SC-CAR4BRAIN for children and young adults with DIPG, DMG or relapsed or refractory CNS tumors? How does SC-CAR4BRAIN work against CNS tumors?

Who can participate in the study?

This study might be a good fit for children and young adults who: Are ages 1 to 26 years old Have DIPG, DMG or a refractory or recurrent CNS tumor. Researchers use many other factors to decide whether a patient can take part in a study (inclusion criteria) or cannot take part (exclusion criteria). The study team at Seattle Children’s can explain what these factors mean for you or your child.

Study Team: